BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 27013159)

  • 1. Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience.
    Fischell TA; Ebner A; Gallo S; Ikeno F; Minarsch L; Vega F; Haratani N; Ghazarossian VE
    JACC Cardiovasc Interv; 2016 Mar; 9(6):589-98. PubMed ID: 27013159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension.
    Mahfoud F; Renkin J; Sievert H; Bertog S; Ewen S; Böhm M; Lengelé JP; Wojakowski W; Schmieder R; van der Giet M; Parise H; Haratani N; Pathak A; Persu A
    JACC Cardiovasc Interv; 2020 Feb; 13(4):471-484. PubMed ID: 32081241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation renal denervation: chemical "perivascular" renal denervation with alcohol using a novel drug infusion catheter.
    Fischell TA; Fischell DR; Ghazarossian VE; Vega F; Ebner A
    Cardiovasc Revasc Med; 2015 Jun; 16(4):221-7. PubMed ID: 25979565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and performance of the second generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.
    Worthley SG; Wilkins GT; Webster MW; Montarello JK; Delacroix S; Whitbourn RJ; Warren RJ
    Atherosclerosis; 2017 Jul; 262():94-100. PubMed ID: 28531827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension.
    Fengler K; Ewen S; Höllriegel R; Rommel KP; Kulenthiran S; Lauder L; Cremers B; Schuler G; Linke A; Böhm M; Mahfoud F; Lurz P
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications.
    Mahfoud F; Weber M; Schmieder RE; Lobo MD; Blankestijn PJ; Persu A; Fischell TA; Parise H; Pathak A; Kandzari DE
    Am Heart J; 2021 Sep; 239():90-99. PubMed ID: 34052211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of renal denervation in elderly patients with resistant hypertension.
    Ziegler AK; Bertog S; Kaltenbach B; Id D; Franke J; Hofmann I; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2015 Aug; 86(2):299-303. PubMed ID: 23983010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension.
    Weber MA; Kirtane AJ; Weir MR; Radhakrishnan J; Das T; Berk M; Mendelsohn F; Bouchard A; Larrain G; Haase M; Diaz-Cartelle J; Leon MB
    JACC Cardiovasc Interv; 2020 Feb; 13(4):461-470. PubMed ID: 32081240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
    Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter.
    Prochnau D; Lucas N; Kuehnert H; Figulla HR; Surber R
    EuroIntervention; 2012 Jan; 7(9):1077-80. PubMed ID: 21959556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN).
    Fengler K; Rommel KP; Blazek S; Besler C; Hartung P; von Roeder M; Petzold M; Winkler S; Höllriegel R; Desch S; Thiele H; Lurz P
    Circulation; 2019 Jan; 139(5):590-600. PubMed ID: 30586691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study.
    Verheye S; Ormiston J; Bergmann MW; Sievert H; Schwindt A; Werner N; Vogel B; Colombo A
    EuroIntervention; 2015 Feb; 10(10):1221-9. PubMed ID: 25452198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model.
    Fischell TA; Vega F; Raju N; Johnson ET; Kent DJ; Ragland RR; Fischell DR; Almany SL; Ghazarossian VE
    EuroIntervention; 2013 May; 9(1):140-7. PubMed ID: 23685302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Man Experience with a Novel Catheter-Based Renal Denervation System of Ultrasonic Ablation in Patients with Resistant Hypertension.
    Chernin G; Szwarcfiter I; Scheinert D; Blessing E; Diehm N; Dens J; Walton A; Verheye S; Shetty S; Jonas M
    J Vasc Interv Radiol; 2018 Aug; 29(8):1158-1166. PubMed ID: 29921526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system.
    Papademetriou V; Tsioufis CP; Sinhal A; Chew DP; Meredith IT; Malaiapan Y; Worthley MI; Worthley SG
    Hypertension; 2014 Sep; 64(3):565-72. PubMed ID: 24935940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study.
    Kaltenbach B; Franke J; Bertog SC; Steinberg DH; Hofmann I; Sievert H
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):335-9. PubMed ID: 22807098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
    Krum H; Schlaich M; Whitbourn R; Sobotka PA; Sadowski J; Bartus K; Kapelak B; Walton A; Sievert H; Thambar S; Abraham WT; Esler M
    Lancet; 2009 Apr; 373(9671):1275-81. PubMed ID: 19332353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.
    Worthley SG; Tsioufis CP; Worthley MI; Sinhal A; Chew DP; Meredith IT; Malaiapan Y; Papademetriou V
    Eur Heart J; 2013 Jul; 34(28):2132-40. PubMed ID: 23782649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symplicity multi-electrode radiofrequency renal denervation system feasibility study.
    Whitbourn R; Harding SA; Walton A
    EuroIntervention; 2015 May; 11(1):104-9. PubMed ID: 25982652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse Wave Velocity Predicts Response to Renal Denervation in Isolated Systolic Hypertension.
    Fengler K; Rommel KP; Hoellriegel R; Blazek S; Besler C; Desch S; Schuler G; Linke A; Lurz P
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28515119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.